Sun Pharma to buy U.S.-based Organon for $11.75 billion
Business
Sun Pharma just got the thumbs up from Organon's shareholders to buy the U.S.-based company in a massive $11.75 billion all-cash deal ($14 per share).
Announced back in April 2026, this move means Organon will soon be fully owned by Sun Pharma's US arm.
Deal could strengthen Sun Pharma globally
If regulators give the final go-ahead, Sun Pharma will get a much bigger presence in the US and globally.
The deal is set to help Sun Pharma grow stronger in the pharma world by bringing Organon's operations under its wing.